María-Victoria Mateos, MD, PhD, shares the results of a subset analysis of TOURMALINE-MM1, which showed that patients with prior exposure to proteasome inhibitors still benefited from ixazomib treatment.
Ixazomib Benefit Persists Despite Prior Therapy in TOURMALINE-MM1 Subset Analysis
Recent Articles
Opioid Overdose Tops List of Leading Causes of Death in the U.S.
The odds of dying from an accidental opioid overdose in the U.S. are greater than those of dying in a car accident, according to...
U.S. Veterans to Have Increased Access to Private Care
As part of the Mission Act of 2018, the U.S. Department of Veterans Affairs (VA) is planning to allow veterans to use their health...
Biosimilar Misinformation Campaigns Lead to Corporate Fight
U.S. Food and Drug Administration (FDA) officials are concerned that drug companies are spreading misinformation about biosimilar versions of their products, potentially undermining confidence...
A Priority for Both Parties: Lowering Drug Costs
Reining in skyrocketing pharmaceutical pricing has been a priority of the Trump administration, and lawmakers have recently ramped up efforts to introduce legislation that...
FDA to Create a New Office to Evaluate Cutting-Edge Science
The U.S. Food and Drug Administration (FDA) plans to create a new department called the Office of Drug Evaluation Science (ODES) that will standardize...
Current Issue
January 2019 Annual Meeting Edition
This issue features highlights from the 2018 ASH Annual Meeting, including big data initiatives to improve prognosis in myelodysplastic syndromes, and more.
